Gubra A/S

Price Chart

Risk-Adjusted Performance

Gubra A/S (GUBRA) Price Performance

Gubra A/S (GUBRA) trades on Nasdaq Copenhagen in DKK. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at DKK360.00, down 4.86% from the previous close.

Over the past year, GUBRA has traded between a low of DKK308.57 and a high of DKK534.00. The stock has lost 6.8% over this period. It is currently 32.6% below its 52-week high.

Gubra A/S has a market capitalization of $6.19B, with a price-to-earnings ratio of 3.69.

About Gubra A/S

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.